Comparative Pharmacology
Head-to-head clinical analysis: NORETHINDRONE AND MESTRANOL versus NORLUTATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHINDRONE AND MESTRANOL versus NORLUTATE.
NORETHINDRONE AND MESTRANOL vs NORLUTATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone is a progestin that suppresses gonadotropin secretion, primarily luteinizing hormone (LH), thereby inhibiting ovulation. Mestranol is a prodrug of ethinyl estradiol, an estrogen that provides negative feedback on the hypothalamic-pituitary-ovarian axis, further suppressing follicle-stimulating hormone (FSH) and LH. The combination stabilizes the endometrium and alters cervical mucus consistency to impede sperm penetration.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial transformation.
1 tablet (norethindrone 1 mg / mestranol 0.05 mg) orally once daily for 21 days, then 7 days off.
5 mg orally once daily for 5 days, starting on day 1 of menstrual cycle; for menorrhagia, 5 mg orally three times daily from day 19 to day 26 of cycle.
None Documented
None Documented
Norethindrone: 5-12 hours; Mestranol: 50-120 minutes (mestranol is rapidly demethylated to ethinyl estradiol, which has a half-life of 10-20 hours). Clinical context: Steady-state is achieved within 5-7 days; no clinically significant accumulation under normal dosing.
Terminal elimination half-life is approximately 5-6 hours. Clinical context: supports twice-daily dosing; steady state reached within 2 days.
Renal (30-50% as metabolites), biliary/fecal (35-55% as metabolites and conjugated forms).
Primarily renal (approximately 60% of metabolites, mostly glucuronides), with about 40% fecal/biliary elimination. Less than 1% excreted unchanged.
Category D/X
Category C
Progestin
Progestin